Depression affects millions of Americans each year, yet many people struggle to find treatments that work. In this video, Maurizio Fava, MD, the psychiatrist-in-chief in the Department of Psychiatry and director of the Division of Clinical Research in the Research Institute at Massachusetts General Hospital, discusses the challenges of current medications and his work to find better options.
Q&A with Dr. Fava
The Department of Psychiatry at Massachusetts General Hospital welcomed Maurizio Fava, MD, as the new leader of the department on October 1, 2019. Dr. Fava brings a wealth of experience to the role and has deep roots within the department—he came to Mass General as a resident, then joined the psychiatry staff in 1988. In this Q&A, he reflects on his outlook as he takes over as chair of the department.
We would like to thank the participating investigators, our collaborators at Syneos Health and our colleagues at the Massachusetts General Hospital (MGH) Clinical Trials Network and Institute, whose contribution was critical to controlling the placebo response.
About the Phase 2 CLARITY Study
The study was conducted in collaboration with the MGH Clinical Trials Network & Institute (CTNI) and randomized 207 adult patients with a confirmed inadequate response to existing first-line selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) therapy for MDD across 27 U.S. clinical research centers.
Anger is an emotional and physical feeling that makes people want to warn, intimidate or attack a person who is perceived as threatening. Fava says a depressed adult with lots of anger is often assumed to have bipolar disorder or a personality disorder.
A small study published in Depression & Anxiety now suggests intravenous (IV) ketamine may be able to reduce symptoms in patients with anxious depression.